LIFECODES® Donor Specific Antibody Assay
Detect donor-specific HLA antibodies against Class I and/or Class II antigens.
Detect donor-specific HLA antibodies against Class I and/or Class II antigens.
The DSA assay makes it possible to screen for the presence of antibodies directed against the HLA antigens of the donor. It is ideal for pre- and post-transplant testing.
- Detect donor specific HLA IgG antibodies against Class I and/or Class II antigens in a single well
- Freeze donor lysate for future testing
- No cell viability issues
- Run from 1 to 91 assays at a time
Research Use Only (RUO). Not for use in diagnostic procedures.
Resource Library
Our Certifications
Related Products
- Testimonial
- Transplant
- Customer
The fact that Immucor representatives are former transplant technologists adds one more layer of support for us. I appreciate Immucor's commitment to comprehensive customer support, from assay and software development to technical and educational support. It's a team approach between vendor and customer that is more than a business relationship. It's a joint mission to benefit patients.
Ellen Klohe, PhD, D(ABHI), HLA Laboratory Director, Vitalant Spokane Laboratory, USA
- Testimonial
- Transplant
- Customer
Immucor products enable us to accurately assign HLA antibody specificities for better transplant outcomes!
Sam Ho, PhD, D(ABHI), FAACC, HLA Lab Director, Gift of Hope Organ & Tissue Donor Network, USA
- Testimonial
- Transplant
- Customer
I really appreciate Immucor's continuous interest in listening to the customer. That is what makes Immucor a great partner to our labs. I know that our needs and ideas will be heard and taken into consideration to improve the products. That makes a world of difference to us in the labs and is truly appreciated.
Valia Bravo-Egana, PhD, F(ACHI), MBA, Director, Technical Supervisor and Clinical Consultant, Histocompatibility/Immunology Laboratory, Medical College of Georgia, USA
Upcoming Events,
Webinars & Workshops
Keep Up With Us
News & Blogs
Werfen Completes Acquisition of Immucor, Inc.
WERFEN COMPLETES ACQUISITION OF IMMUCOR, INC., EXPANDING LEADERSHIP IN SPECIALIZED DIAGNOSTICS Werfen announced in November 2022 that it reached an agreement to acquire Immucor, Inc. for approximately US$2 billion. The transaction has received all necessary regulatory approvals. The Transfusion and...
News & Blogs
EFI 2023 - Bienvenue à Nantes, France!
Immucor is excited to see you at EFI 2023 - Bienvenue à Nantes, France! As...
News & Blogs
MIA FORATM NGS EXPRESS HLA Typing Software: You Spoke, We Listened!
Introducing MIA FORA NGS EXPRESS HLA Typing Software, Immucor’s next step in providing value-added user...
News & Blogs
Coming Soon: Detect DP with LIFECODES® LifeScreen Deluxe!
Immucor is in the process of improving our LIFECODES® LifeScreen Deluxe (LMX) to add DP...
News & Blogs
CUSTOMER SPOTLIGHT: Mid-South Transplant Foundation, Inc. C3d Validation and Implementation
For all histocompatibility laboratories, Complement-Dependent Cytotoxicity (CDC) testing proves to be time consuming and tedious...
